EGFR and cancer: Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as erlotinib, gefitinib, and afatinib, provide favorable treatment outcomes in EGFR-mutation-positive patients, the overall survival rate of NSCLC patients remains low, and most NSCLC patients experience cancer recurrence and metastasis [4,5,6,7].